Fig. 5.
Ability of the Bayesian approach to estimate pharmacokinetic parameters when doses of a drug conforming to a one-compartment model with nonlinear elimination as described in Fig. 3. Significant correlations between the true patient values and the Bayesian estimates are shown. The ka and km were not significant. The half-life shown is the expected value when a dose is given that is well below the km of the drug (calculated as . Data construction and sampling are as described in Fig. 3.